SOCIETY: AASLD

METABOLIC OUTCOMES AND KEY EFFICACY DATA FROM A PHASE 2 TRIAL EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS

EFFECT OF OBETICHOLIC ACID ON APRI SCORE IN PATIENTS AT HIGHER RISK FOR FIBROSIS, AS DETERMINED BY HIGHER BASELINE FIBROSIS-4 SCORE AND LIVER STIFFNESS: SUBANALYSIS OF THE PHASE 3 POISE TRIAL IN PRIMARY BILIARY CHOLANGITIS

MULTI-OMIC SEQUENCING REVEALS DISTINCTIVE GENE EXPRESSION AND DNA METHYLATION ALTERATIONS AS POTENTIAL PREDICTORS OF PRIMARY SCLEROSING CHOLANGITIS DEVELOPMENT IN TREATMENT-NAÏVE PAEDIATRIC ULCERATIVE COLITIS

METABOLIC BIOMARKERS PREDICT THE OUTCOME OF UDCA TREATMENT ON PBC PATIENTS WITH HIGH ACCURACY

PATHOLOGICAL CHARACTERISTICS AND ROLE OF PLASMA CELLS IN REFRACTORY PRIMARY BILIARY CHOLANGITIS: IMPLICATIONS FOR TARGETED THERAPY

FOLIC ACID DEFICIENCY EXACERBATES BILIARY INFLAMMATION IN PRIMARY BILIARY CHOLANGITIS BY PROMOTING CHOLANGIOCYTE SENESCENCE

Alan Bonder

Appearances